By Chris Wack
UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for Huntington's disease.
Shares were recently trading at $16.13, hitting a 52-week high.
The gene therapy company said that, as part of its late November meeting, the FDA agreed that data from the ongoing Phase 1/2 studies may serve as the primary basis for a biologics license application submission.
Under the accelerated approval pathway, this would allow UniQure to avoid the need for an additional pre-submission study.
The FDA granted the Lexington, Mass., company a regenerative medicine advanced therapy designation for AMT-130 in May. The designation said that preliminary clinical data from the ongoing Phase 1/2 studies indicate AMT-130 has the potential to address unmet medical needs for the treatment of Huntington's disease.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 10, 2024 10:03 ET (15:03 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.